Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research
2024
Latest Therapeutical Approaches for Triple-Negative Breast Cancer
publication
Evidence: moderate
Author Information
Author(s): Mariona Pont, Marta Marqués, Anabel Sorolla
Primary Institution: Biomedical Research Institute of Lleida (IRBLleida)
Conclusion
The study outlines current therapies and emerging treatments for triple-negative breast cancer (TNBC), highlighting the challenges and future directions in its management.
Supporting Evidence
- Triple-negative breast cancer (TNBC) accounts for 30-40% of breast cancer deaths.
- Current treatments for TNBC include chemotherapy, immunotherapy, and targeted therapies.
- Emerging therapies such as epigenetic modulators and CRISPR show promise in treating TNBC.
Takeaway
Triple-negative breast cancer is hard to treat because it doesn't have the usual markers that help doctors choose treatments, but new therapies are being developed to help fight it.
Limitations
The study discusses the high heterogeneity of TNBC and the lack of effective targeted therapies as significant challenges.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website